FDA approves Benlysta to treat lupus

360

The US Food and Drug Administration approved Benlysta (belimumab) to treat patients with active, autoantibody-positive lupus (systemic lupus erythematosus) who are receiving standard therapy, including corticosteroids, antimalarials, immunosuppressives, and nonsteroidal anti-inflammatory drugs, the approval was announced on 9 March 2011.

 

Benlysta (benlimumab) is a monoclonal antibody, delivered directly by intravenous infusion that acts against B-lymphocyte stimulator, a protein that is thought to increase production of white blood cells that attack healthy tissue. It is present in elevated levels in lupus patients. 

 

Prior to Benlysta, the FDA last approved drugs to treat lupus, Plaquenil (hydroxychloroquine) and corticosteroids, in 1955. Aspirin was approved to treat lupus in 1948.

 

Two clinical studies involving 1,684 patients with lupus demonstrated the safety and effectiveness of Benlysta. The studies diagnosed patients with active lupus and randomised them to receive Benlysta plus standard therapy, or an inactive infused solution (placebo) plus standard therapy. The studies excluded patients who had received prior B-cell targeted therapy or intravenous cyclophosphamide, and those who had active lupus involving the kidneys or central nervous system.

 

Patients treated with Benlysta and standard therapies experienced less disease activity than those who received a placebo and standard of care medicines. Results suggested, but did not definitively establish, that some patients had a reduced likelihood of severe flares, and some reduced their steroid doses. 

 

African American patients and patients of African heritage participating in the two studies did not appear to respond to treatment with Benlysta. The studies lacked sufficient numbers to establish a definite conclusion. An additional study to further evaluate the safety and effectiveness of Benlysta for this subgroup of lupus patients has been agreed.

 

Those receiving Benlysta during clinical studies reported more deaths and serious infections compared with placebo. The drug should not be administered with live vaccines. The manufacturer is required to provide a Medication Guide to inform patients of the risks associated with Benlysta.

 

The most common side effects in the studies included nausea, diarrhea, and fever (pyrexia). Patients also commonly experienced infusion reactions, so pre-treatment with an antihistamine should be considered.

 

Human Genome Sciences, based in Rockville, USA, developed Benlysta and will co-market the drug in the United States with GlaxoSmithKline of Philadelphia.

(Visited 33 times, 1 visits today)